BridgeMD
A trial to learn if AZD5492 is safe and works alone and in combination with other cancer treatments in adults with B-cell blood cancers.
EU CTIS ID: 2024-511099-34-00
What this study is testing
The objective of the study is to assess the safety and tolerability of AZD5492 as monotherapy or in combination with other anticancer agents in participants with R/R B-cell malignancies.
- Human Pharmacology (Phase I)- First administration to humans
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ≥18 years of age
- The above is a summary, other inclusion criteria details may apply
- Histologically documented CD20+ mature B-cell neoplasm
- Large B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
You likely can't join if
- Any neoplasm histology not specified in the IC section
- Active CNS involvement in lymphoma or CNS pathology.
- CNS pathology including but not limited to any history of seizure disorder/epilepsy
- Prior allogeneic HSCT within 180 days, prior autologous HSCR within 90 days, or cell therapy within 90 days of start of therapy.
- History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS.
- Active and uncontrolled infections.
See the full eligibility criteria
- ≥18 years of age
- The above is a summary, other inclusion criteria details may apply
- Histologically documented CD20+ mature B-cell neoplasm
- Large B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy
- ECOG performance status of = 2 (Note: in EU countries this inclusion is ECOG performance status of < 2).
- Any neoplasm histology not specified in the IC section
- Active CNS involvement in lymphoma or CNS pathology.
- CNS pathology including but not limited to any history of seizure disorder/epilepsy
- Prior allogeneic HSCT within 180 days, prior autologous HSCR within 90 days, or cell therapy within 90 days of start of therapy.
- History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS.
- Active and uncontrolled infections.
- Unresolved AEs ≥2 Grade, from prior therapies.
- The above is a summary, other exclusion criteria details may apply.
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- United States
- China
- Canada
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; United States; China; Canada; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.